

TARPSWG INTERNATIONAL TUMOR BOARD

Jason Sicklick, MD, FACS

Professor of Surgery, Division of Surgical Oncology

Adjunct Professor, Department of Pharmacology

Executive Vice Chair of Research, Department of Surgery


Leader, Sarcoma Disease Team, Moores Cancer Center

UC San Diego Health | UC San Diego School of Medicine

WHAT DEFINES RPS RESECTABILITY?


THREE FACTORS

1. Patient-related factors (e.g., co-morbidities)
2. Disease biology
3. Technical aspects



RETROPERITONEAL SARCOMA

Biology & Involvement are Broad & Variable



1. Tumors tend to have multi-visceral involvement
2. Variable disease biology (depending on histology & grade)
3. Variable responsiveness to systemic therapies

Difficult to define strict technical criteria of unresectability

OBJECTIVE

To convene RPS specialists from around the world in a monthly Virtual Tumor Board to discuss challenging cases that were initially reviewed at ≥ 1 sarcoma centers and deemed to be borderline resectable or unresectable.






17 Virtual Tumor Boards

May 2021 – October 2022

4th Friday of each month (1 hour)






CASE SUBMISSION

1. Presenter name
2. Institution
3. Patient age & sex
4. Tumor histology
5. Primary vs. metastatic disease
6. Number of prior operations
7. Number of lines of systemic chemotherapy
8. Prior radiation: Yes or No
9. Major concern and/or question regarding resectability




Attendance and Case Presentations

	Median	Range
Attendees	22	15 - 74
Cases (N=47)	3	1 - 4
Presenters (N=36)	1	1 - 7







Attendance and Case Presentations






4 Continents 15 Countries 26 Institutions



11 Tumor Histologies



Recurrent themes of challenging cases included:

1. Recurrent LPS encasing a solitary remnant kidney following contralateral nephrectomy
2. LPS encasing a transplanted kidney
3. Tumor abutment of the small bowel mesenteric root & SMA
4. Primary LMS of the IVC with extensive tumor thrombus



Polling

- **Post-hoc survey of presenters [12/31 responses (39%) in June 2022], the discussion:**
 - Confirmed management: 2/3 cases
 - Change in management: 1/3 cases



SUMMARY

- The International Tumor Board has provided **broad expert opinion from sarcoma specialists** spanning the globe with aims to:
 - 1) **Better understand RPS resectability**
 - 2) **Learn & teach new approaches for tackling challenging technical aspects of RPS resections**
 - 3) **Elevate RPS care worldwide**



FUTURE DIRECTIONS & DISCUSSION

- Suggestions for overall improvements?
- Suggestions for increasing engagement beyond the core 20-25 that religiously attend?
- Additional meeting times:
 - North America, South America, Europe, Middle East?
 - East Asia & Australia?
- Manuscript after 20th tumor board?



TARPSWG International Tumor Board

JOIN US



jsicklick@health.ucsd.edu

SESSION 1, TALK 1

CREATION AND IMPLEMENTATION OF A MONTHLY INTERNATIONAL TUMOR BOARD: EXPERIENCE OF THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)

THANK YOU TO ALL COAUTHORS AND PARTICIPANTS!



Role: Co-Author
Carol Swallow, MD, PhD
Professor, University of Toronto
Email: carol.swallow@sinaihhealth.ca



Role: Co-Author
Chandrajit Raut, MD, MSc, FACS, FSSO (he/him/his)
Surgical Oncologist, Brigham and Women's Hospital/Harvard Medical School
Email: crout@bwh.harvard.edu
Office Telephone: (617) 632-5982
Cell Phone: (617) 530-0322



Role: Co-Author
Dario Callegaro, MD
Surgical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori
Email: dario.callegaro@istitutotumori.mi.it



Role: Co-Author
Marko Novak, MD
Surgical Oncologist, Department of Surgical Oncology, Institute of Oncology Ljubljana
Email: mnovak@onko-l.si



Role: Co-Author
Raza Sayyed, FRCSEd, EBSQ (Surg Onc)
Sarcoma Fellow, The Royal Marsden Hospital
Email: raza.sayyed@gmail.com
Office Telephone: 07983736722



Role: Co-Author
Dirk Strauss, MMed, FCS, FRCS
Surgical Oncologist, Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust
Email: dirk.strauss@rmh.nhs.uk



Role: Co-Author
Samuel Aguiar, Jr, MD
TARPSWG
Email: samuel.aguiar.jr@gmail.com



Role: Co-Author
Sylvie Bonvalot, MD PhD
Head, Sarcoma Surgery, Institut Curie - Paris, FRANCE
Email: sylvie.bonvalot@curie.fr
Cell Phone: 0033613500482



Role: Co-Author
Jeffrey Farma, MD, FACS (he/him/his)
Interim Chair of Surgery, Professor of Surgical Oncology, Fox Chase Cancer Center
Email: jeffrey.farma@fccc.edu
Cell Phone: (215) 459-2698



Role: Co-Author
Matthieu Faron, MD, PhD
Surgical Oncologist, Department of Surgical Oncology, Institut Gustave Roussy
Email: mattieu.faron@gustaveroussy.fr



Role: Co-Author
Juan Angel Fernández, N/A, MD, PhD
"La Arrixaca" University Hospital
Email: jaferher@outlook.com



Role: Co-Author
Andrew Hayes, MD PhD
Consultant Surgical Oncologist, Royal Marsden Hospital
Email: andrew.hayes@rmh.nhs.uk
Office Telephone: 00442078118081
Cell Phone: 00447985203848



Role: Co-Author
Shintaro Iwata, MD
Staff physician, National Cancer Center Hospital
Email: shiwata@ncc.go.jp
Office Telephone: 81335422511



Role: Co-Author
Guy Lahat, MD
TARPSWG
Email: guylahat@gmail.com



Role: Co-Author
Andrea Laurenzi, MD (he/him/his)
Consultant, Division of Hepatobiliary Surgery and Organ Transplantation Azienda Ospedaliero-Universitaria di Bologna - IRCCS
Email: andrea.laurenzi@aosp.bo.it



Role: Co-Author
Fabian Johnston, MD
Surgical Oncologist, The Johns Hopkins University School of Medicine
Email: fjohnst4@jhmi.edu



Role: Co-Author
Giovanni Grignani, MD
Medical Oncologist, Department of Medical Oncology-Sarcoma Unit, Candiolo Cancer Institute FPO-IRCCS, Candiolo (TO), Italy
Email: giovanni.grignani@ircc.it
Office Telephone: 00390119933623
Cell Phone: (011) 993-3628



Role: Co-Author
Allison Maciver, MD (she/her/hers)
Surgical Oncologist, London Health Sciences Centre
Email: allison.maciver@lhsc.on.ca
Office Telephone: 519685850053658



Role: Co-Author
Joshua Mammen, MD
Professor and Division Chief, University of Nebraska
Email: jmammen@unmc.edu
Office Telephone: (402) 559-7298



Role: Co-Author
Kjell Ovrebo, MD
TARPSWG
Email: kjell.kare.ovrebo@helse-bergen.no



Role: Co-Author
Sameer Rastogi, MD
Additional Professor, TARPSWG
Email: samdoc_mamc@yahoo.com



Role: Co-Author
Piotr Rutkowski, MD, PhD
Head of Department of Soft Tissue/Bone Sarcoma and Melanoma, Professor of Surgical Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Email: piotr.rutkowski@pib-nio.pl
Office Telephone: 48225462184
Cell Phone: +48501153384



Role: Co-Author
Catherine Sarre, MD
TARPSWG
Email: sarrecatherine@gmail.com



Role: Co-Author
Jacek Skoczylas, MD
TARPSWG
Email: jacus.skoczylas@gmail.com



Role: Co-Author
William Tseng, MD
TARPSWG
Email: wtseng@coh.org



Role: Co-Author
Dimitri Tzanis, MD, PhD
Surgical Oncologist, Department of Surgical Oncology, Institut Curie
Email: dimitri.tzanis@curie.fr



Role: Co-Author
Jiping Wang, MD (he/him/his)
Associate Director, Hepatobiliary Cancer, Division of Surgical Oncology, TARPSWG
Email: jwang39@bwh.harvard.edu
Office Telephone: (617) 525-6563



Role: Co-Author
Marco Fiore, MD, FACS, FEBS
Surgical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori
Email: marco.fiore@istitutotumori.mi.it
Office Telephone: (339) 598-1381



Role: Co-Author
Alessandro Gronchi, MD, FSSO (he/him/his)
Surgical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori
Email: Alessandro.Gronchi@istitutotumori.mi.it